Since 1898, Roswell Park Cancer Institute (RPCI), America's first cancer center, has forged an exemplary reputation based on the combined strength of its basic/translational research, multidisciplinary oncology teams, educational programs and compassionate staff. A seamless interface of scientific inquiry and clinical application, and an aggressive clinical trials program, afford patients access to promising breakthroughs in cancer diagnostics, technology and therapies. RPCI is the only facility in Upstate New York to hold the National Cancer Institute designation of "comprehensive cancer center." Its mission is to understand, prevent and cure cancer.

RPCI has been credited with initiating the world's first chemotherapy studies, and pioneering the prostate-specific antigen (PSA) test and photodynamic therapy. Specialized treatments include high-priority protocols and new therapeutic regimens based on the most recent advances in biochemical pharmacology, genetics, immunology, and biological response modifiers. Specialized programs have been established for blood and marrow transplantation, neuro-oncology, pigmented tumors, genetic counseling and testing, long-term survivors of childhood cancer, pain management, photodynamic therapy, robotics, and minimally invasive surgery (Gamma Knife, brachytherapy, RFA, VATS, etc).

In addition:

� The Institute's Center for Pharmacology & Therapeutics is one of only a few centers in the nation capable of taking drug development from conception stage through clinical trials and FDA approval within the confines of a single institution.

� Roswell Park has become a significant contributor to basic, translational and clinical prostate cancer research in the United States. RPCI investigators have taken a national leadership role in laboratory and clinical studies of vitamin D and prostate cancer.

� RPCI's Blood and Marrow Transplant Program is certified by the National Marrow Donor Program as a Transplant, Collection and Apheresis Center.

� RPCI is one of a few Transplant Programs to have a clinical and molecular epidemiologist who provides analysis of clinical data as a basis for developing interventions to improve the clinical care of transplant patients.

� RPCI is one of only a handful of centers in the nation to offer Interleukin-2 therapy for metastatic kidney cancer.

� RPCI geneticists created the first gene library that was used to map and sequence the human genome. An RPCI geneticist was one of a handful of researchers who led teams involved in the international effort to map the human genome.

� RPCI immunologists are exploring new therapies-such as cytokines, monoclonal antibodies, and vaccines-that boost, direct, or restore the body's normal defenses against cancer. Recent "translational" investigations include:

o Clinical studies on Rituxan, the first FDA-approved monoclonal antibody for treating non-Hodgkin lymphoma.

o Studies on hyperthermia-a process by which the whole body temperature is raised two to three degrees above normal. By raising a person's temperature, the immune system may be stimulated against tumors in much the same way that natural fevers help fight off infections.

o Studies on how tumors avoid the immune system by confining themselves to a limited number of tissues and organs. By delivering drugs that stimulate the immune response directly into these "compartments," physicians can gain the advantage in this cellular game of hide-and-seek.

� RPCI is poised to become a leader in phase I/phase II evaluation of new drugs.

� RPCI has opened one of the first Clinical Research Centers in the nation that focuses specifically on the treatment and care of patients participating in Phase I and Phase II clinical research studies.

� RPCI maintains registries for individuals with a genetic predisposition to certain cancers.

� RPCI epidemiologists, behavioral scientists, cancer prevention experts, biostatisticians, and other applied researchers conduct important cancer studies on tobacco control, chemoprevention, high-risk populations, long-term effects of treatment, screening and early detection strategies, nutrition and lifestyle, environmental exposures, and stress and coping, among others.

� RPCI's comprehensive health disparities program aggressively advances community-based research to reduce, eliminate and prevent health disparities in underserved populations.

� In conjunction with the National Comprehensive Cancer Network, RPCI physicians and administrators have taken a national leadership role in crafting and implementing national measurement/benchmarking tools to define quality.

� RPCI leads the nation in the number of robotic cystectomies performed.

Over the last decade, RPCI has undergone major renovation and expansion, adding nearly 200 faculty, opening a new hospital facility and a $74 million Center for Genetics & Pharmacology, and forming strategic partnerships with research and clinical investigators and medical centers throughout the state and nation.

Committing the infrastructure, intellectual capital, and necessary resources to convert its scientific discoveries into real-world products/applications, RPCI established three biotech spin-off companies with the potential to change the future of cancer medicine.

RPCI ranks among the nation�s top 1% of cancer centers and teaching hospitals for patient satisfaction with physician services and overall care; and among the top research centers funded by the NCI/NIH.

In April of 2007, Donald L. Trump, MD, was appointed President and CEO. In addition to his role as President and CEO, Dr. Trump continues his work as a researcher and clinician, leading the Institute's active clinical research in vitamin D-based cancer prevention and treatment, caring for patients with prostate cancer and other urologic cancers.

He also will continue as principal investigator or co-principal investigator on several grants funded by the National Cancer Institute and Department of Defense. He holds European and U.S. patents for the use of vitamin D and vitamin D analogues in combination with high-dose chemotherapy.

RPCI's Vital Statistics

� One of the top 20 employers in Western New York

� Cited as one of "The Best Places to Work" in WNY by Business First

� Over 3,200 employees including 256 physicians & senior scientists, and over 500 nurses

� Hospital Admissions: 4,539

� Outpatient Visits: 168,845

� Patients Under Active Care: 26,041

� Patient Origin: 39 States, 7 Foreign Countries

� Number of Beds: 112

� Average Length of Stay: 7.1 days

� Results of Patient Satisfaction Surveys: Over 98 percent of Roswell Park patients consistently rate the care at Roswell Park as excellent or very good and over 97 percent of patients say they would recommend Roswell Park to other cancer patients.

Research/Biotechnology

� Grants/Contracts: $89.1 million

� Research and development agreements: 169 collaborations

� 65 licenses

� 119 patents

� Funded Research Projects: 522

Biotech Spin-offs and Research Partners

� AndroBioSys

� Cleveland BioLabs, Inc.

� Empire Genomics

� Hauptman-Woodward Medical Research Institute

� NYS Center of Excellence in Bioinformatics & Life Sciences, University at Buffalo

� PersonaDX

Affiliations/Satellites

� Amherst Center, Williamsville, NY (chemotherapy and infusion center)

� Bradford Regional Medical Center, Bradford, PA (network affiliate)

� Cayuga Medical Center, Ithaca, NY (radiation oncology satellite and network affiliate)

� King Hussein Cancer Center, Amman, Jordan (network affiliate)

� King Hussein Cancer Biotechnology Institute, Amman Jordan (network affiliate; research, clinical and education programs)

� Olean General Hospital, Olean, NY (radiation satellite and network affiliate)

� Rochester General Hospital, Rochester, NY (network affiliate)

� Semmelweiss University, Szeged University, Medical School of Pecs, University of Debrecan Medical and Health Science Center, Hungary (education)

� University of Puerto Rico, Rio Peidras Campus (education)

� WCA Hospital, Jamestown, NY (radiation satellite and network affiliate)

� Zhejiang University, Hangzhou, China (research and education programs)

E-mail

Mark A A Size

	Quick Links
Clinical Practice Guidelines Drugs & Biologics Compendium Chemotherapy Order Templates Educational Events CME/CE Programs For Patients: NCCN.com Find an NCCN Member Institution Clinical Practice Guidelines Find Clinical Trials Permissions Requests Case Manager Training Member Institution Profiles Clinical Practice Guidelines Drugs & Biologics Compendium Permissions Requests Supporters and Exhibitors Oncology Research Program Corporate Council Permissions Requests NCCN Academy NCCN Business Insights, Research & Analytics NCCN Flash Updates NCCN Trends Surveys Permissions Requests